| Peer-Reviewed

Joint Detection of High-Risk HPV E6/E7 mRNA and HC2 HPV-DNA in Cervical Lesions Screening

Received: 3 April 2023     Accepted: 8 May 2023     Published: 22 May 2023
Views:       Downloads:
Abstract

Objective To explore the value of joint detection of high-risk HPV E6/E7 mRNA and HC2 HPV-DNA to the screening of cervical lesions. Methods Totally 869 patients were divided into low-grade squamous intraepithelial lesions negative group including normal, inflammation and low-grade squamous intraepithelial lesions, and high-grade squamous intraepithelial lesions (HSIL) positive group including HSIL, squamous cell carcinoma and adenocarcinoma confirmed by ThinPrep cytologic test, HC2 HPV-DNA, high-risk HPV E6/E7 mRNA detection and colposcopy biopsy. The pathological result on HSIL positive was as the gold standard to evaluate the value of joint detection of HC2 HPV-DNA and high-risk HPV E6/E7 mRNA to the screening of cervical cancer. Results The positive rates of HPV E6/E7 mRNA and HPV-DNA detection in 869 patients were 46.1% and 61.3%, and increased with the severity of cytological grade and cervical level (P<0.05). The sensitivity and specificity of HPV E6/E7 mRNA were 97.4% and 64.9%, higher than those of HPV-DNA (89.0%, 44.6%) (P<0.05). The sensitivity and specificity of joint detection of HPV E6/E7 mRNA and HPV-DNA were 99.3% and 56.7%. The overall consistency rate and positive consistency rate were higher for HSIL positive (87.6%, 87.0%) than those for HSIL negative (70.5%, 30.5%) (P<0.05). Conclusion The positive expressions of HPV E6/E7 mRNA and HPV-DNA are closely correlated with the severity of cervical lesions, and the joint detection of them two has high sensitivity and specificity.

Published in World Journal of Public Health (Volume 8, Issue 2)
DOI 10.11648/j.wjph.20230802.24
Page(s) 134-138
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2023. Published by Science Publishing Group

Keywords

Cervical Lesions, Human Papillomavirus, HPV E6/E7 mRNA, HPV-DNA

References
[1] HERRERO R, GONZÁLEZ P, MARKOWITZ L E. Present status of human papillomavirus vaccine development and implementation [J]. Lancet Oncol, 2015, 16 (5): e206-216.
[2] WANG Q, SONG R, ZHAO C, et al. HPV 16 E6 promotes cervical cancer cell migration and invasion by down-regulation of NHERFl [J]. Int J Cancer, 2019, 144 (7): 1477-1765.
[3] Boniface Uji Ago. A Review of the Molecular Pathways of Oncogenic HPV and Targeted the Rapies in Carcinoma of the Uterine Cervix [J]. Advances in Surgical Sciences. 2017, 5 (1): 1-6. doi: 10.11648/j.ass.20170501.11.
[4] GAO Y, YUE W T. Research progress of human papillomavirus carcinogenic mechanism and related vaccines [J]. Int J Virol, 2019, 26 (1): 69-72.
[5] ZHU D, YE M, ZHANG W. E6/E7 oncoproteins of high risk HPV-16 up-regulate MT1-MMP, MMP-2 and MMP-9 and promote the migration of cervical cancer cells [J]. Int J Clin Exp Pathol, 2015, 8 (5): 4981-4989.
[6] SOLOMON D, DAVEY D, KUMAN R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology [J]. JAMA, 2002, 287 (16): 2114-2119.
[7] MOCKEL J, QUAAS J, MEISEL H, et al. Human papillomavirus E6/E7 mRNA testing has higher specificity than liquid-based DNA testing in the evaluation of cervical intraepithelial neoplasia [J]. Anal Quant Cytol Histol, 2011, 33 (6): 311-315.
[8] CLAD A, REUSCHENBACH M, WEINSCHENK J, et al. Performance of the Aptima high-risk human papillomavirus mrRNA assay in a referral population in comparison with hybrid capture 2 and cytology [J]. Clin Microbiol, 2011, 49 (3): 1071-1076.
[9] Li Hong, Huang Ying, Feng Yuan, et al. Effect of Aptima HPV E6E7 mRNA on detection of high-grade cervical lesions [J]. China Maternal and Child Health Care, 2019, 34 (18): 4183-4185.
[10] ZHAO X Y, CUI Y, JIANG S F, et al. The significance of high-risk human papillomavirus E6/E7 mRNA detection in cervical cancer screening [J]. Natl Med J China, 2014, 94 (43): 3432-3435.
[11] Du Caiying, Li Fang. Comparison of human papillomavirus DNA and E6/E7 mRNA detection in cervical lesion diagnosis [J]. Chinese Journal of Eugenics and Genetics, 2015, 23 (4): 38-40.
[12] Tang Zhenli, Su Guang, Wang Yan, et al. Application value of high risk human papilloma virus E6/E7 mRNA in cervical screening for CIN2+ lesions [J]. Journal of Anhui Medicine, 2019, 40 (2): 122-125.
[13] Zhang Shengzhi, Shao Huajiang, Ma Jianting. Application of human papillomavirus E6/E7mRNA detection in cervical lesion screening [J]. Chinese Journal of Experimental Diagnostics, 2014, 18 (4): 582-585.
[14] CASTLE P E, REID J, DOCKTER J, et al. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology [J]. Clin Virol, 2015, 69: 52-55.
[15] BENEVOLO M, VOCATURO A, CARACENI D, et al. Sensitivity, specificity, and clinical value of human papillomavirus (HPV) E6/E7 mRNA assay as a triage test for cervical cytology and HPV DNA test [J]. Clin Microbiol, 2011, 49 (7): 2643-2650.
[16] Eshetu Dadi Gurmu, Purnachandra Rao Koya. Sensitivity Analysis and Modeling the Impact of Screening on the Transmission Dynamics of Human Papilloma Virus (HPV) [J]. American Journal of Applied Mathematics. 2019, 7 (3): 70-79. doi: 10.11648/j.ajam.20190703.11.
[17] Intisar Salim Pity. Pregnant and Postpartum Women with Atypical Glandular Cells: Follow-up and Evaluation for High-Risk HPV [J]. Cancer Research Journal. 2013, 1 (4): 31-36. doi: 10.11648/j.crj.20130104.11.
Cite This Article
  • APA Style

    Huang Shanshan, Xu Fengjuan, Cheng Yan, Gu Fenghua, Gu Guojian. (2023). Joint Detection of High-Risk HPV E6/E7 mRNA and HC2 HPV-DNA in Cervical Lesions Screening. World Journal of Public Health, 8(2), 134-138. https://doi.org/10.11648/j.wjph.20230802.24

    Copy | Download

    ACS Style

    Huang Shanshan; Xu Fengjuan; Cheng Yan; Gu Fenghua; Gu Guojian. Joint Detection of High-Risk HPV E6/E7 mRNA and HC2 HPV-DNA in Cervical Lesions Screening. World J. Public Health 2023, 8(2), 134-138. doi: 10.11648/j.wjph.20230802.24

    Copy | Download

    AMA Style

    Huang Shanshan, Xu Fengjuan, Cheng Yan, Gu Fenghua, Gu Guojian. Joint Detection of High-Risk HPV E6/E7 mRNA and HC2 HPV-DNA in Cervical Lesions Screening. World J Public Health. 2023;8(2):134-138. doi: 10.11648/j.wjph.20230802.24

    Copy | Download

  • @article{10.11648/j.wjph.20230802.24,
      author = {Huang Shanshan and Xu Fengjuan and Cheng Yan and Gu Fenghua and Gu Guojian},
      title = {Joint Detection of High-Risk HPV E6/E7 mRNA and HC2 HPV-DNA in Cervical Lesions Screening},
      journal = {World Journal of Public Health},
      volume = {8},
      number = {2},
      pages = {134-138},
      doi = {10.11648/j.wjph.20230802.24},
      url = {https://doi.org/10.11648/j.wjph.20230802.24},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.wjph.20230802.24},
      abstract = {Objective To explore the value of joint detection of high-risk HPV E6/E7 mRNA and HC2 HPV-DNA to the screening of cervical lesions. Methods Totally 869 patients were divided into low-grade squamous intraepithelial lesions negative group including normal, inflammation and low-grade squamous intraepithelial lesions, and high-grade squamous intraepithelial lesions (HSIL) positive group including HSIL, squamous cell carcinoma and adenocarcinoma confirmed by ThinPrep cytologic test, HC2 HPV-DNA, high-risk HPV E6/E7 mRNA detection and colposcopy biopsy. The pathological result on HSIL positive was as the gold standard to evaluate the value of joint detection of HC2 HPV-DNA and high-risk HPV E6/E7 mRNA to the screening of cervical cancer. Results The positive rates of HPV E6/E7 mRNA and HPV-DNA detection in 869 patients were 46.1% and 61.3%, and increased with the severity of cytological grade and cervical level (PPPConclusion The positive expressions of HPV E6/E7 mRNA and HPV-DNA are closely correlated with the severity of cervical lesions, and the joint detection of them two has high sensitivity and specificity.},
     year = {2023}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Joint Detection of High-Risk HPV E6/E7 mRNA and HC2 HPV-DNA in Cervical Lesions Screening
    AU  - Huang Shanshan
    AU  - Xu Fengjuan
    AU  - Cheng Yan
    AU  - Gu Fenghua
    AU  - Gu Guojian
    Y1  - 2023/05/22
    PY  - 2023
    N1  - https://doi.org/10.11648/j.wjph.20230802.24
    DO  - 10.11648/j.wjph.20230802.24
    T2  - World Journal of Public Health
    JF  - World Journal of Public Health
    JO  - World Journal of Public Health
    SP  - 134
    EP  - 138
    PB  - Science Publishing Group
    SN  - 2637-6059
    UR  - https://doi.org/10.11648/j.wjph.20230802.24
    AB  - Objective To explore the value of joint detection of high-risk HPV E6/E7 mRNA and HC2 HPV-DNA to the screening of cervical lesions. Methods Totally 869 patients were divided into low-grade squamous intraepithelial lesions negative group including normal, inflammation and low-grade squamous intraepithelial lesions, and high-grade squamous intraepithelial lesions (HSIL) positive group including HSIL, squamous cell carcinoma and adenocarcinoma confirmed by ThinPrep cytologic test, HC2 HPV-DNA, high-risk HPV E6/E7 mRNA detection and colposcopy biopsy. The pathological result on HSIL positive was as the gold standard to evaluate the value of joint detection of HC2 HPV-DNA and high-risk HPV E6/E7 mRNA to the screening of cervical cancer. Results The positive rates of HPV E6/E7 mRNA and HPV-DNA detection in 869 patients were 46.1% and 61.3%, and increased with the severity of cytological grade and cervical level (PPPConclusion The positive expressions of HPV E6/E7 mRNA and HPV-DNA are closely correlated with the severity of cervical lesions, and the joint detection of them two has high sensitivity and specificity.
    VL  - 8
    IS  - 2
    ER  - 

    Copy | Download

Author Information
  • Department of Obstetrics and Gynecology, Taicang Hospital Affiliated to Soochow University, Suzhou, China

  • Department of Obstetrics and Gynecology, Taicang Hospital Affiliated to Soochow University, Suzhou, China

  • Department of Obstetrics and Gynecology, Taicang Hospital Affiliated to Soochow University, Suzhou, China

  • Department of Pathology, Taicang Hospital Affiliated to Soochow University, Suzhou, China

  • Department of Pathology, Taicang Hospital Affiliated to Soochow University, Suzhou, China

  • Sections